RxDoctor Payments DataLook up a doctor →

John Clark, MD

Internal Medicine · Huntsville, ALNPI 1578631784

Payments from drug & device makers

$756,287in general payments, 2019–2025

Across 330 payments — averaging $2291.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vertex$677K
  • Boehringer Ingelheim$63K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$6K
  • Boehringer Ingelheim International GmbH$3K
  • Medtronic$2K
  • Bard Peripheral Vascular, Inc.$1K
  • plus $5K from 30 others

What the payments were for

  • Speaking & faculty fees$1252%
  • Travel & lodging$1,81122%
  • Food & beverage$6,31476%
  • Education$220%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$756,287 in reported general payments places this provider in the 95th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$343,469
Medicare patients
520
Services billed
2,263

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide39$80,390
KerendiaFinerenone58$46,183
RayaldeeCalcifediol22$38,110
Paricalcitol144$30,565
LokelmaSodium Zirconium Cyclosilicate28$25,570
JardianceEmpagliflozin12$13,670
Sevelamer Carbonate77$11,217
Lanthanum Carbonate13$6,492
Clonidine11$3,311
Calcium Acetate12$1,470
Nifedipine ErNifedipine44$1,367
Calcitriol46$1,098
Losartan Potassium97$1,092
Cinacalcet Hcl21$798
Potassium Chloride24$698

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$81$80,39039 claims
BayerKerendia$475$46,18358 claims
OPKO Pharmaceuticals, LLCRayaldee$407$38,11022 claims
AstraZenecaLokelma$482$25,57028 claims
Boehringer IngelheimJardiance$62,987$13,67012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Huntsville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →